Phase Ib/IIa trial of TapImmune's TPIV-100 vaccine in patients with HER2/neu-positive breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2018
Price : $35 *
At a glance
- Drugs TPIV 100 (Primary)
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- 17 Oct 2018 According to a Marker Therapeutics Inc, the TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc.
- 05 Apr 2018 According to a TapImmune media release, this study is fully funded by a grant from the U.S. DoD.
- 15 Nov 2017 According to a TapImmune media release, this trial is expected to begin in 1H 2018.